Mycobacterium Infections is an indication for drug development with over 300 pipeline drugs currently active. According to GlobalData, preregistered drugs for Mycobacterium Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Mycobacterium Infections compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Mycobacterium Infections overview
Mycobacteria are a group of bacteria that includes various species, some of which can cause infections in humans. The most well-known mycobacterial species is Mycobacterium tuberculosis, which causes tuberculosis (TB). Mycobacterial infections vary in severity and clinical presentation, and the appropriate treatment approach depends on the specific species involved and the characteristics of the infection. Early diagnosis, proper management, and public health measures are essential in controlling mycobacterial infections
For a complete picture of PTSR and LoA scores for drugs in Mycobacterium Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
